title: [ANALYSIS OF PRIMARY TREATMENT AND PROGNOSIS OF SPONTANEOUS URTICARIA IN A LOCAL CLINIC OF OFFICE DERMATOLOGY].
abstract: BACKGROUND
  Prognosis of spontaneous urticaria in association with early treatment remained unclear. In this study, we retrospectively studied the prognosis of acute spontaneous urticaria in relation to age and treatments in a local clinic of dermatology.
  
  
  METHODS
  Out of 5000 patients who visited an office dermatology clinic, clinical records of patients with spontaneous urticaria were extracted. Their prognosis and the relation to age and treatments were analyzed by the Kaplan-Meier method and generalized Wilcoxon test.
  
  
  RESULTS
  Among 386 patients diagnosed as spontaneous urticaria, 284 patients (73.6%) had begun treatments within a week after the onset. The non-remission rates of them after one week, four week and one year from the onset were 26.8%, 15.0% and 6.7%, respectively. The non-remission rate of patients who were 20-years-old or younger by one year after the onset of urticaria, was significantly lower than that of patients older than 20-years-old. No apparent relations between the remission rate and sex or the use of steroids was detected. However, the non-remission rate of urticaria that was treated with a standard dose of antihistamine was lower than that treated with additional medications.
  
  
  CONCLUSIONS
  Most patients who began treatments within one week from the onset remitted shortly. However approximately 7% of them continued to suffer from symptoms for more than a year. Such prolongation tends to be seen among patients who required other medications in addition to standard dose of antihistamine.
authors.affiliation: Tanaka Dermatology Clinic.
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Tanaka
authors.forename: Makiko
authors.initials: M
authors.lastname: Hiragun
authors.forename: Michihiro
authors.initials: M
authors.lastname: Hide
authors.forename: Takaaki
authors.initials: T
authors.lastname: Hiragun
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000554:Ambulatory Care Facilities / Q000706:statistics & numerical data*; D001623:Betamethasone / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D003880:Dermatology / Q000706:statistics & numerical data*; D004359:Drug Therapy, Combination; D005260:Female; D006633:Histamine Antagonists / Q000008:administration & dosage; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D011379:Prognosis; D013997:Time Factors; D014581:Urticaria / Q000188:drug therapy* / Q000453:epidemiology*; D055815:Young Adult
chemical_list: D006633:Histamine Antagonists; D001623:Betamethasone; D011239:Prednisolone